The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 24, 2013
Filed:
Jul. 01, 2010
William M. Switzer, Stone Mountain, GA (US);
Walid Heneine, Atlanta, GA (US);
Thomas M. Folks, Helotes, TX (US);
Nathan D. Wolfe, Los Angeles, CA (US);
Donald S. Burke, Pittsburgh, PA (US);
Eitel Mpoudi Ngole, Yaoundé, CM;
William M. Switzer, Stone Mountain, GA (US);
Walid Heneine, Atlanta, GA (US);
Thomas M. Folks, Helotes, TX (US);
Nathan D. Wolfe, Los Angeles, CA (US);
Donald S. Burke, Pittsburgh, PA (US);
Eitel Mpoudi Ngole, Yaoundé, CM;
The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention, Washington, DC (US);
Johns Hopkins University, Baltimore, MD (US);
Abstract
Disclosed are compositions and methods related to the isolation and identification of the primate T-lymphotropic viruses, HTLV-3 and HTLV-4. The diversity of HTLVs was investigated among central Africans reporting contact with NHP blood and body fluids through hunting, butchering, and keeping primate pets. Herein it is shown that this population is infected with a variety of HTLVs, including two retroviruses; HTLV-4 is the first member of a novel phylogenetic lineage that is distinct from all known HTLVs and STLVs; HTLV-3 falls within the genetic diversity of STLV-3, a group that has not previously been seen in humans. The present disclosure also relates to vectors and vaccines for use in humans against infection and disease. The disclosure further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-3 and HTLV-4 and related viruses.